EMA Application withdrawn: Advexin — Gendux Molecular Limited

View source ↗

Summary

The EMA status shows the Advexin application has been withdrawn for Li-Fraumeni Syndrome by Gendux Molecular Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Li-fraumeni Syndrome

Drugs mentioned

• Advexin (contusugene ladenovec)

Snippet

Status: Application withdrawn. Therapeutic area: Li-Fraumeni Syndrome. MAH: Gendux Molecular Limited. Decision date: 31/12/2009. Orphan medicine